Healthy, no Evidence of Disease, Lung Cancer
Conditions
Keywords
squamous cell lung cancer, non-small cell lung cancer, small cell lung cancer, healthy, no evidence of disease
Brief summary
RATIONALE: Studying samples of blood, urine, sputum, mouth cells, and bronchial tissue from healthy participants in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors learn more about the development of cancer. PURPOSE: This laboratory study is looking for molecular markers in predicting lung cancer development using tissue samples from healthy participants.
Detailed description
OBJECTIVES: * To obtain biological specimens from healthy participants with no known risk of lung cancer to use as controls in the study of lung cancer progression. * To identify new molecular abnormalities specific to the development of squamous cell carcinoma of the lung. OUTLINE: Serum, urine, sputum, and buccal cell samples are collected. Patients also undergo bronchoscopy for collection of bronchial tissue and bronchial brush samples. The samples are used for genomic and proteomic studies to identify new molecular abnormalities specific to the development of lung cancer.
Interventions
GENETICproteomic profiling
Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
OTHERbiologic sample preservation procedure
Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
OTHERlaboratory biomarker analysis
Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
PROCEDUREbronchoscopy
Collection of breath condensate.
Sponsors
National Cancer Institute (NCI)
Vanderbilt-Ingram Cancer Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
DISEASE CHARACTERISTICS: * Healthy participant * No history of smoking * No history of cancer PATIENT CHARACTERISTICS: * SWOG performance status 0 * No clinically apparent bleeding diathesis PRIOR CONCURRENT THERAPY: * Not specified
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Collection of biological specimens to use as controls in the study of lung cancer progression | Off study date, up to one year | Specimens are collected from healthy participants with no known risk of lung cancer |
Secondary
| Measure | Time frame |
|---|---|
| Identification of new molecular abnormalities specific to the development of squamous cell carcinoma of the lung | off-study date, up to one year |
| Selection of important genes/proteins differentially expressed between study groups (e.g., normal vs low-grade vs high-grade vs invasive) and between normal smokers vs normal non-smokers | off-study date, up to one year |
Countries
United States
Outcome results
None listed